Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Jun 4 2010

Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.  The antibody's intended use is to promote clearance of the amyloid beta toxin from the brain, which leads to Alzheimer's disease.   A Notice of Allowance is a written communication from the USPTO stating that the application has been allowed and will be granted as a U.S. patent after payment of the Government issue fee.  The patent application that was allowed claims two different monoclonal antibodies, originally designated as 82E1 and 1A10, each of which binds a different end of the amyloid beta protein and not the amyloid precursor protein from which amyloid beta is metabolically generated.  This key safety feature is consistent with the ANTISENILIN^® monoclonal antibody platform invented by Dr. Daniel Chain, the Company's Chairman and CEO.

Dr. Chain commented: "The Notice of Allowance for a new patent by the USPTO is an important milestone, broadening our overall intellectual property portfolio and bolstering the competitive advantage of our internal drug development pipeline, which boasts clinical stage and preclinical programs.  IN-N01 is designed to specifically reduce the amount of amyloid beta protein accumulating in the fluids surrounding the brain and to reduce plaque.  In addition, IN-N01 has unique inherent features that suggest it may directly inhibit the neurotoxicity of amyloid beta, which accumulates in the brains of Alzheimer's patients, while minimizing the potential for adverse effects.  We hope that IN-N01 will be useful to treat a potentially broader population of Alzheimer's patients at earlier stages of the disease compared to similar drugs currently being developed by major pharmaceutical companies."